Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
Titel:
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
Auteur:
Geerlinks, Ashley V. Scull, Brooks Krupski, Christa Fleischmann, Ryan Pulsipher, Michael A. Eapen, Mary Connelly, James A. Bollard, Catherine M. Pai, Sung-Yun Duncan, Christine N. Kean, Leslie S. Baker, K. Scott Burroughs, Lauri M. Andolina, Jeffrey R. Shenoy, Shalini Roehrs, Philip Hanna, Rabi Talano, Julie-An Schultz, Kirk R. Stenger, Elizabeth O. Lin, Howard Zoref-Lorenz, Adi McClain, Kenneth L. Jordan, Michael B. Man, Tsz-Kwong Allen, Carl E. Marsh, Rebecca A.